Latest On Catalyst Pharmaceuticals, Inc (CPRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 18:16 EST | News | Catalyst Pharmaceuticals (CPRX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 03:27 EST | News | Catalyst Pharmaceuticals beats Q1 top and bottom line estimates; reaffirms FY23 outlook | N/A | |
| 2023-05-10 01:27 EST | News | Catalyst Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-04-19 09:17 EST | News | Catalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy Task | N/A | |
| 2023-04-18 21:51 EST | News | Catalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A Thread | N/A | |
About Catalyst Pharmaceuticals, Inc (CPRX):
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets read more.... The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
General
- Name Catalyst Pharmaceuticals, Inc
- Symbol CPRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 74
- Fiscal Year EndDecember
- IPO Date2006-11-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.catalystpharma.com
Valuation
- Trailing PE 5.93
- Forward PE 12.25
- Price/Sales (Trailing 12 Mt.) 3.77
- Price/Book (Most Recent Quarter) 2.59
- Enterprise Value Revenue 2.51
- Enterprise Value EBITDA 7.08
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.36
- Next Year EPS Estimate $0.46
- Next Quarter EPS Estimate $0.08
- Profit Margin 63%
- Operating Margin 35%
- Return on Assets 17%
- Return on Equity 58%
- Revenue 119.07 million
- Earnings Per Share $0.71
- Revenue Per Share $1.15
- Gross Profit 87.12 million
- Quarterly Earnings Growth 3%
Highlights
- Market Capitalization 437.1 million
- EBITDA 41.4 million
- PE Ratio 35.27
- Analyst Target Price $7.5
- Book Value Per Share $1.63
Share Statistics
- Shares Outstanding 103.83 million
- Shares Float 86.56 million
- % Held by Insiders 698%
- % Held by Institutions 69.58%
- Shares Short 8.4 million
- Shares Short Prior Month 9.21 million
- Short Ratio 4.4
- Short % of Float 9%
- Short % of Shares Outstanding 8%
Technicals
- Beta 1.35
- 52 Week High $5.19
- 52 Week Low $2.88
- 50 Day Moving Average 4.04
- 200 Day Moving Average 3.53
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Catalyst Pharmaceuticals, Inc (CPRX) Dividend Calendar:
Catalyst Pharmaceuticals, Inc (CPRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Catalyst Pharmaceuticals, Inc (CPRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Catalyst Pharmaceuticals, Inc (CPRX) Chart:
Catalyst Pharmaceuticals, Inc (CPRX) News:
Below you will find a list of latest news for Catalyst Pharmaceuticals, Inc (CPRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Catalyst Pharmaceuticals, Inc (CPRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CPRX Trades:
Catalyst Pharmaceuticals, Inc (CPRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-06 | 8-K (Current report) | |
| 2020-09-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-30 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-30 | 8-K (Current report) | |
| 2020-09-11 | 8-K (Current report) | |
| 2020-08-26 | 8-K (Current report) | |
| 2020-08-21 | 8-K (Current report) | |
| 2020-08-20 | 8-K (Current report) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-08-03 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-07-31 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-07-31 | EFFECT (Notice of Effectiveness) | |
| 2020-07-30 | UPLOAD (SEC-generated letter) | |
| 2020-07-30 | CORRESP (Correspondence) | |
| 2020-07-23 | S-3 (Registration statement under Securities Act of 1933) | |
Catalyst Pharmaceuticals, Inc (CPRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Catalyst Pharmaceuticals, Inc (CPRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 698%
Institutional Ownership: 6958%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | PATRICK J MCENANY | President and CEO | Buy | 15,000.00 | 2.97 | 44,550.00 | 4,787,693.00 | |
| 2020-09-30 | Charles B O'Keeffe | Director | Buy | 7,000.00 | 2.99 | 20,930.00 | 560,376.00 | |
| 2019-12-05 | GARY INGENITO | Chief Medical Officer | Sell | 150,000.00 | 4.82 | 723,150.00 | 0.00 | |
| 2019-12-04 | GARY INGENITO | Chief Medical Officer | Buy | 150,000.00 | 2.53 | 379,500.00 | 150,000.00 | |
| 2019-11-27 | GARY INGENITO | Chief Medical Officer | Sell | 100,000.00 | 4.66 | 466,000.00 | 0.00 | |
| 2019-11-27 | GARY INGENITO | Chief Medical Officer | Buy | 100,000.00 | 1.13 | 113,000.00 | 100,000.00 | |
| 2019-11-21 | GARY INGENITO | Chief Medical Officer | Sell | 100,000.00 | 4.50 | 449,800.00 | 0.00 | |
| 2019-11-20 | GARY INGENITO | Chief Medical Officer | Buy | 100,000.00 | 0.79 | 79,000.00 | 100,000.00 | |
| 2019-10-11 | Charles B O'Keeffe | Director | Buy | 10,000.00 | 4.70 | 46,950.00 | 553,376.00 | |
| 2019-10-03 | PATRICK J MCENANY | President and CEO | Buy | 10,000.00 | 4.89 | 48,900.00 | 4,772,693.00 | |
| 2019-06-11 | PATRICK J MCENANY | President and CEO | Buy | 25,000.00 | 3.23 | 80,750.00 | 4,762,693.00 | |
| 2018-12-27 | DONALD A DENKHAUS | Director | Buy | 25,000.00 | 1.91 | 47,750.00 | 225,000.00 | |
| 2018-12-19 | PATRICK J MCENANY | President and CEO | Buy | 20,000.00 | 2.24 | 44,800.00 | 4,737,693.00 | |
| 2018-12-14 | DONALD A DENKHAUS | Director | Buy | 60,000.00 | 2.48 | 148,800.00 | 200,000.00 | |
| 2018-12-14 | Charles B O'Keeffe | Director | Buy | 20,000.00 | 2.50 | 50,000.00 | 543,376.00 | |
| 2018-06-08 | DONALD A DENKHAUS | Director | Buy | 20,000.00 | 3.41 | 68,200.00 | 140,000.00 | |
| 2018-06-07 | Charles B O'Keeffe | Director | Buy | 4,000.00 | 3.31 | 13,222.00 | 522,376.00 | |
| 2018-06-07 | Charles B O'Keeffe | Director | Buy | 1,000.00 | 3.35 | 3,352.30 | 523,376.00 | |
| 2018-06-01 | Charles B O'Keeffe | Director | Buy | 5,000.00 | 3.74 | 18,680.00 | 518,376.00 | |
| 2018-05-30 | DONALD A DENKHAUS | Director | Buy | 20,000.00 | 3.75 | 75,000.00 | 120,000.00 | |